Home > Insider Trading > Filing (0001439222-25-000082)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1439222	Agios Pharmaceuticals Inc.	AGIO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1881190	Sarah Gheuens	88 Sidney Street Cambridge MA 02139	Chief Medical Officer	No	Yes	No	No

Transaction Summary

Sold:	11,914 shares	Avg. Price: $37.99	Total Value: $452,601.03
Number of Shares After Transactions:	61,271 shares

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-07-09	11,914	$25.01	73,185	No	4	M	Direct
Common Stock	Disposition	2025-07-09	11,067	$37.93	62,118	No	4	S	Direct
Common Stock	Disposition	2025-07-09	847	$38.76	61,271	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock options (right to buy)	Disposition	2025-07-09	11,914	$0.00	11,914	$25.01

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
32,086		2033-03-01	No	4	M	Direct

Footnotes

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $37.52 to $38.49. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $38.55 to $38.87. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.